The Association Between Drospirenone and Hyperkalemia

A Comparative-safety Study

Steven T Bird; Salvatore R Pepe; Mahyar Etminan; Xinyue Liu; James M Brophy; Joseph AC Delaney


BMC Clin Pharmacol. 2011;11(23):1-6. 

In This Article


In a large cohort of young women, drospirenone did not cause a clinically significant increase in risk for hyperkalemia when compared with other progestin-containing OCs. It is however concerning that, despite the bolded warning for hyperkalemia, drospirenone and spironolactone are used together preferentially. This likely demonstrates a channeling of patients with premenstrual dysphoric disorder and polycystic ovary syndrome to use of drospirenone. Furthermore, physicians are not following the monitoring requirements for serum potassium assays in the package insert for patients taking these two medications.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: